Efficacies of Cabotegravir and Bictegravir Against Drug-resistant HIV-1 Integrase Mutants

Overview

Journal Retrovirology

Publisher Biomed Central

Specialty Microbiology

Date 2018 May 18

PMID 29769116

Citations 57

Authors

Steven J Smith

Xue Zhi Zhao

Terrence R Burke Jr

Stephen H Hughes

Affiliations

Soon will be listed here.

Abstract

Background: Integrase strand transfer inhibitors (INSTIs) are the class of antiretroviral (ARV) drugs most recently approved by the FDA for the treatment of HIV-1 infections. INSTIs block the strand transfer reaction catalyzed by HIV-1 integrase (IN) and have been shown to potently inhibit infection by wild-type HIV-1. Of the three current FDA-approved INSTIs, Dolutegravir (DTG), has been the most effective, in part because treatment does not readily select for resistant mutants. However, recent studies showed that when INSTI-experienced patients are put on a DTG-salvage therapy, they have reduced response rates. Two new INSTIs, Cabotegravir (CAB) and Bictegravir (BIC), are currently in late-stage clinical trials.

Results: Both CAB and BIC had much broader antiviral profiles than RAL and EVG against the INSTI-resistant single, double, and triple HIV-1 mutants used in this study. BIC was more effective than DTG against several INSTI-resistant mutants. Overall, in terms of their ability to inhibit a broad range of INSTI-resistant IN mutants, BIC was superior to DTG, and DTG was superior to CAB. Modeling the binding of CAB, BIC, and DTG within the active site of IN suggested that the "left side" of the INSTI pharmacophore (the side away from the viral DNA) was important in determining the ability of the compound to inhibit the IN mutants we tested.

Conclusions: Of the two INSTIs in late stage clinical trials, BIC appears to be better able to inhibit the replication of a broad range of IN mutants. BIC retained potency against several of the INSTI-resistant mutants that caused a decrease in susceptibility to DTG.

Citing Articles

An Ultra-Long-Acting Dimeric Bictegravir Prodrug Defined by a Short Pharmacokinetic Tail.

Edagwa B, Nayan M, Sillman B, Das S, Hanson B, Sultana A Res Sq. 2025; .

PMID: 40034436 PMC: 11875291. DOI: 10.21203/rs.3.rs-5959131/v1.

Comparative Analyses of Antiviral Potencies of Second-Generation Integrase Strand Transfer Inhibitors (INSTIs) and the Developmental Compound 4d Against a Panel of Integrase Quadruple Mutants.

Smith S, Zhao X, Hughes S, Burke Jr T Viruses. 2025; 17(1).

PMID: 39861910 PMC: 11768864. DOI: 10.3390/v17010121.

HIV-1 Integrase T218I/S Polymorphisms Do Not Reduce HIV-1 Integrase Inhibitors' Phenotypic Susceptibility.

Rodriguez-Lopez E, Lopez P, Rodriguez Y, Sanchez R, Acevedo V, Encarnacion J AIDS Res Hum Retroviruses. 2024; 41(1):43-54.

PMID: 39086253 PMC: 11807902. DOI: 10.1089/AID.2023.0128.

HIV-1 diversity and pre-treatment drug resistance in the era of integrase inhibitor among newly diagnosed ART-naïve adult patients in Luanda, Angola.

Sebastiao C, Abecasis A, Jandondo D, Sebastiao J, Vigario J, Comandante F Sci Rep. 2024; 14(1):15893.

PMID: 38987263 PMC: 11237101. DOI: 10.1038/s41598-024-66905-1.

Design, synthesis and biological evaluation of indole-2-carboxylic acid derivatives as novel HIV-1 integrase strand transfer inhibitors.

Zhang R, Chen G, Wang W, Wang Y, Zhang W, Chen T RSC Adv. 2024; 14(13):9020-9031.

PMID: 38500630 PMC: 10945512. DOI: 10.1039/d3ra08320a.

References

Goethals O, Clayton R, Van Ginderen M, Vereycken I, Wagemans E, Geluykens P . Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors. J Virol. 2008; 82(21):10366-74. PMC: 2573211. DOI: 10.1128/JVI.00470-08. View

Zhao X, Smith S, Maskell D, Metifiot M, Pye V, Fesen K . HIV-1 Integrase Strand Transfer Inhibitors with Reduced Susceptibility to Drug Resistant Mutant Integrases. ACS Chem Biol. 2016; 11(4):1074-81. PMC: 4836387. DOI: 10.1021/acschembio.5b00948. View

Oliveira Passos D, Li M, Yang R, Rebensburg S, Ghirlando R, Jeon Y . Cryo-EM structures and atomic model of the HIV-1 strand transfer complex intasome. Science. 2017; 355(6320):89-92. PMC: 5508583. DOI: 10.1126/science.aah5163. View

Johnson V, Calvez V, Gunthard H, Paredes R, Pillay D, Shafer R . Update of the drug resistance mutations in HIV-1: March 2013. Top Antivir Med. 2013; 21(1):6-14. PMC: 6148891. View

Shah B, Schafer J, DeSimone Jr J . Dolutegravir: a new integrase strand transfer inhibitor for the treatment of HIV. Pharmacotherapy. 2013; 34(5):506-20. DOI: 10.1002/phar.1386. View

Neogi U, Singh K, Aralaguppe S, Rogers L, Njenda D, Sarafianos S . Ex-vivo antiretroviral potency of newer integrase strand transfer inhibitors cabotegravir and bictegravir in HIV type 1 non-B subtypes. AIDS. 2017; 32(4):469-476. PMC: 5790636. DOI: 10.1097/QAD.0000000000001726. View

Yoshinaga T, Kobayashi M, Seki T, Miki S, Wakasa-Morimoto C, Suyama-Kagitani A . Antiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection. Antimicrob Agents Chemother. 2014; 59(1):397-406. PMC: 4291378. DOI: 10.1128/AAC.03909-14. View

Castagna A, Maggiolo F, Penco G, Wright D, Mills A, Grossberg R . Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis. 2014; 210(3):354-62. PMC: 4091579. DOI: 10.1093/infdis/jiu051. View

Smith S, Hughes S . Rapid screening of HIV reverse transcriptase and integrase inhibitors. J Vis Exp. 2014; (86). PMC: 4165338. DOI: 10.3791/51400. View

10.

van Lunzen J, Maggiolo F, Arribas J, Rakhmanova A, Yeni P, Young B . Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis. 2011; 12(2):111-8. DOI: 10.1016/S1473-3099(11)70290-0. View

11.

Quashie P, Mesplede T, Han Y, Veres T, Osman N, Hassounah S . Biochemical analysis of the role of G118R-linked dolutegravir drug resistance substitutions in HIV-1 integrase. Antimicrob Agents Chemother. 2013; 57(12):6223-35. PMC: 3837891. DOI: 10.1128/AAC.01835-13. View

12.

Mesplede T, Osman N, Wares M, Quashie P, Hassounah S, Anstett K . Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity. J Antimicrob Chemother. 2014; 69(10):2733-40. PMC: 4164141. DOI: 10.1093/jac/dku199. View

13.

Das K, Clark Jr A, Lewi P, Heeres J, de Jonge M, Koymans L . Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1.... J Med Chem. 2004; 47(10):2550-60. DOI: 10.1021/jm030558s. View

14.

Min S, Sloan L, DeJesus E, Hawkins T, McCurdy L, Song I . Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults. AIDS. 2011; 25(14):1737-45. DOI: 10.1097/QAD.0b013e32834a1dd9. View

15.

Ballantyne A, Perry C . Dolutegravir: first global approval. Drugs. 2013; 73(14):1627-37. DOI: 10.1007/s40265-013-0121-4. View

16.

Fransen S, Gupta S, Danovich R, Hazuda D, Miller M, Witmer M . Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J Virol. 2009; 83(22):11440-6. PMC: 2772690. DOI: 10.1128/JVI.01168-09. View

17.

Margot N, Hluhanich R, Jones G, Andreatta K, Tsiang M, McColl D . In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4. Antiviral Res. 2011; 93(2):288-296. DOI: 10.1016/j.antiviral.2011.12.008. View

18.

Yoshinaga T, Seki T, Miki S, Miyamoto T, Suyama-Kagitani A, Kawauchi-Miki S . Novel secondary mutations C56S and G149A confer resistance to HIV-1 integrase strand transfer inhibitors. Antiviral Res. 2018; 152:1-9. DOI: 10.1016/j.antiviral.2018.01.013. View

19.

Gallant J, Thompson M, DeJesus E, Voskuhl G, Wei X, Zhang H . Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1-Infected Adults. J Acquir Immune Defic Syndr. 2017; 75(1):61-66. PMC: 5389589. DOI: 10.1097/QAI.0000000000001306. View

20.

Markowitz M, Frank I, Grant R, Mayer K, Elion R, Goldstein D . Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. Lancet HIV. 2017; 4(8):e331-e340. DOI: 10.1016/S2352-3018(17)30068-1. View